Drug Search Results
More Filters [+]

Tioguanine

Alternative Names: tioguanine, 6-thioguanine, thioguanine
Latest Update: 2024-12-11
Latest Update Note: Clinical Trial Update

Product Description

Tioguanine (TG) is an antimetabolite which may be regarded as an alternative to azathioprine (AZA)/mercaptopurine (MP) in patients with inflammatory bowel diseases. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12940925/)

Mechanisms of Action: DNA Synthesis Inhibitor,RNA Synthesis Inhibitor,GPAT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Czech | Ecuador | Egypt | Estonia | France | Germany | Greece | Hong Kong | India | Ireland | Italy | Jordan | Korea | Lithuania | Malaysia | Malta | Netherlands | New Zealand | Pakistan | Peru | Poland | Romania | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay

Approved Indications: None

Known Adverse Events: None

Company: Douglas Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tioguanine

Countries in Clinic:

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Colitis, Ulcerative|Oral Ulcer|Proctitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ACTRN12624001448538

P1

Not yet recruiting

Oral Ulcer|Colitis, Ulcerative

2025-06-30

ACTRN12623001337662

P1

Not yet recruiting

Oral Ulcer|Proctitis

2024-04-30

Recent News Events